• S Sakura Minami, Vivian Shen, David Le, Grietje Krabbe, Rustam Asgarov, Liberty Perez-Celajes, Chih-Hung Lee, Jinhe Li, Diana Donnelly-Roberts, and Li Gan.
• Gladstone Institute of Neurological Diseases, 1650 Owens St., San Francisco, CA 94158, United States; Department of Neurology, University of California, San Francisco, CA 94158, United States.
• Biochem. Pharmacol. 2015 Oct 15; 97 (4): 454-62.

AbstractMutations in the progranulin gene cause frontotemporal dementia (FTD), a debilitating neurodegenerative disease that involves atrophy of the frontal and temporal lobes and affects personality, behavior, and language. Progranulin-deficient mouse models of FTD exhibit deficits in compulsive and social behaviors reminiscent of patients with FTD, and develop excessive microgliosis and increased release of inflammatory cytokines. Activation of nicotinic acetylcholine receptors (nAChRs) by nicotine or specific α7 nAChR agonists reduces neuroinflammation. Here, we investigated whether activation of nAChRs by nicotine or α7 agonists improved the excessive inflammatory and behavioral phenotypes of a progranulin-deficient FTD mouse model. We found that treatment with selective α7 agonists, PHA-568487 or ABT-107, strongly suppressed the activation of NF-κB in progranulin-deficient cells. Treatment with ABT-107 also reduced microgliosis, decreased TNFα levels, and reduced compulsive behavior in progranulin-deficient mice. Collectively, these data suggest that targeting activation of the α7 nAChR pathway may be beneficial in decreasing neuroinflammation and reversing some of the behavioral deficits observed in progranulin-deficient FTD.Copyright © 2015. Published by Elsevier Inc.

35 keywords...

hide…